ADME-Toxicology Testing Global Market Report 2022: Increased Need to Check Late-Stage Drug Failures Drives Growth –

ADME-Toxicology Testing Global Market Report 2022: Increased Need to Check Late-Stage Drug Failures Drives Growth –

ADME-Toxicology Testing Global Market Report 2022: Increased Need to Check Late-Stage Drug Failures Drives Growth –

DUBLIN–(BUSINESS WIRE)–The “ADME-Toxicology Testing – Global Market Trajectory & Analytics” report has been added to’s offering.

Global ADME-Toxicology Testing Market to Reach $12.3 Billion by 2027

In the changed post COVID-19 business landscape, the global market for ADME-Toxicology Testing estimated at US$6 Billion in the year 2020, is projected to reach a revised size of US$12.3 Billion by 2027, growing at a CAGR of 10.9% over the analysis period 2020-2027. Cell Culture, one of the segments analyzed in the report, is projected to record a 13.4% CAGR and reach US$5.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the High Throughput Screening segment is readjusted to a revised 7.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3 Billion, While China is Forecast to Grow at 15.4% CAGR

The ADME-Toxicology Testing market in the U.S. is estimated at US$3 Billion in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$966.9 Million by the year 2027 trailing a CAGR of 15.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.3% and 12.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.3% CAGR.

Molecular Imaging Segment to Record 9.6% CAGR

In the global Molecular Imaging segment, USA, Canada, Japan, China and Europe will drive the 9.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$974.7 Million in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 79 Featured) –

  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • BioreclamationIVT, LLC
  • CompuDrug International, Inc.
  • Cyprotex PLC.
  • Molecular Discovery Ltd.
  • MultiCASE, Inc.
  • PerkinElmer, Inc.
  • Pharmaron, Inc.
  • Promega Corporation
  • Simulations Plus, Inc.
  • Taconic Biosciences, Inc.
  • Takara Bio Europe AB
  • Tecan Group Ltd.
  • Thermo Fisher Scientific, Inc.

Key Topics Covered:






  • Increased Need to Check Late-Stage Drug Failures Drive Market Growth
  • Steady Increase in Average Drug Development Cost and Efforts to Mitigate Late-Stage Drug Failure Rates Highlights the Role of ADME-Toxicology Testing
  • Impact of ADME-Tox Screening on New Drug Discovery
  • Phase-I Clinical Trial Failures Before and After the Advent of Preclinical ADME/Pharmacokinetics
  • Actors Leading to Failure of Drugs in Phase III Clinical Trials: Percentage Breakdown of Number of Cases for Efficacy, Pharmacokinetics, Toxicity and Others
  • Pharma Industry Renews Focus on Cost Optimization
  • China and India: Hot Spots for R&D Investment
  • Growth Momentum Shifts Away from In Vivo Technologies; In Vitro Technologies to Lead the Charge
  • Growing Prominence of Cell-based Assays in Drug Discovery and ADME Analysis
  • Major Types of Cell-Based HTS Assays for Drug Screening
  • Cell-based Assays in HTS and UHTS
  • Innovation in Screening Guarantees Success for Drug Discovery Programs
  • High-Content Screening (HCS) – An Expanding Technology in Cell-Based Assays
  • High Content Screening – Key Application Areas
  • HCS Market Ripe with Growth Opportunity
  • Increasing Use of Cell-Based Assays over Other Methods in Toxicity Testing
  • 3D Cell Culture Technology to Put a New Spin on In Vitro Cell Analyses
  • CDER’s DARS 2 – Microphysiological 3D Cell Culture Platforms as Drug Development Tools
  • Rising Investment in Proteomics R&D Drive Cell-based Assays Market
  • Automated Multiplexing Platforms Present Growth Opportunities
  • Automation of Cell-based Assays: A Growing Trend
  • In-Silico ADME Emerge as Compelling Drug Discovery & Development Tool
  • Advantages of Using In Silico Approaches
  • Personalized Treatments & Computational Tools: Intriguing Facets of ADME R&D ADME Pharmacogenomics to Power Personalized Treatments
  • In Vitro 3D Organoid Models to Meet ADME-Toxicity Testing Needs
  • Limitations of Traditional in vitro Cellular Models
  • Organoids Technology – Advanced in vitro 3D Platforms for More Physiologically Relevant Modeling
  • Stem Cells Exude Great Potential in Drug Toxicity Testing
  • Global Market for Stem Cell-Assays
  • Functional Assays: An Effective Way of Predicting Specific Toxic Effects
  • GPCR Targets to Drive Growth in Functional Cell Assay Market
  • Molecular Imaging and ADME
  • Organ-on-a-Chip Technology Gains Momentum in ADME Toxicology Testing
  • Technological Advancements in ADME Toxicology Testing



For more information about this report visit


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900